Biotin is an emerging therapy for the treatment of secondary progressive MS.
- Family Member
- Posts: 75
- Joined: Thu May 27, 2010 2:00 pm
- Family Elder
- Posts: 3351
- Joined: Wed Jul 27, 2005 2:00 pm
- Location: Sydney, Australia
A direct link: http://www.medday-pharma.com/news-and-e ... w-funding/
Friday, April 08, 2016
MedDay Secures €34 Million ($38.5M) New Funding
Edmond de Rothschild Investment Partners led the Series B financing alongside existing investors Sofinnova Partners and InnoBio. Large Venture also participated in the operation.
Funds will drive a confirmatory phase 3 study in US to treat progressive multiple sclerosis with MedDay’s wholly-owned lead candidate, MD1003
Does anyone know if the following statement only relates to people who were in the original studies? or is there a method to access the MD100 (as opposed to sourcing your own Biotin)?
The drug is already commercialized in some European countries under “named patient use”.